How to buy Biogen shares

Own Biogen shares in just a few minutes.

Fact checked

Biogen Inc (BIIB) is a leading drug manufacturers—general business based in the US. Biogen is listed on the NASDAQ and employs 7,400 staff. All prices are listed in US Dollars.

How to buy shares in Biogen

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BIIB in this case.
  5. Research Biogen shares. The platform should provide the latest information available.
  6. Buy your Biogen shares. It's that simple.

Biogen share price

Use our graph to track the performance of BIIB stocks over time.

Biogen shares at a glance

Information last updated 2020-09-25.
52-week range$219.7 - $374.99
50-day moving average $280.0606
200-day moving average $290.3916
Wall St. target price$305.14
PE ratio 7.9965
Dividend yield N/A (0%)
Earnings per share (TTM) $34.044
Promoted
eToro Free Stocks

Invest in Biogen shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Your first 50 trades are free with Fineco, until 30/09/2020. T&Cs apply. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Biogen under- or over-valued?

Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biogen's P/E ratio

Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Biogen shares trade at around 8x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Biogen's P/E ratio is best considered in relation to those of others within the drug manufacturers—general industry or those of similar companies.

Biogen's PEG ratio

Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Biogen's PEG ratio in relation to those of similar companies.

Biogen's EBITDA

Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $8 billion.

The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.

To put Biogen's EBITDA into context you can compare it against that of similar companies.

Biogen financials

Revenue TTM $14.5 billion
Operating margin TTM 52.37%
Gross profit TTM $12.4 billion
Return on assets TTM 18.31%
Return on equity TTM 49.38%
Profit margin 40.91%
Book value $71.438
Market capitalisation $42.5 billion

TTM: trailing 12 months

How to short and sell Biogen shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "BIIB.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.3 million Biogen shares held short by investors – that's known as Biogen's "short interest". This figure is 39.1% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Biogen shares can be evaluated.

Biogen's "short interest ratio" (SIR)

Biogen's "short interest ratio" (SIR) is the quantity of Biogen shares currently shorted divided by the average quantity of Biogen shares traded daily (recently around 1.3 million). Biogen's SIR currently stands at 2.63. In other words for every 100,000 Biogen shares traded daily on the market, roughly 2630 shares are currently held short.

To gain some more context, you can compare Biogen's short interest ratio against those of similar companies.

However Biogen's short interest can also be evaluated against the total number of Biogen shares, or, against the total number of tradable Biogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biogen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biogen shares in existence, roughly 20 shares are currently held short) or 0.021% of the tradable shares (for every 100,000 tradable Biogen shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biogen.

Find out more about how you can short Biogen stock.

Biogen's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Biogen's total ESG risk score

Total ESG risk: 23.93

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 23.93 (as at 08/01/2020) is pretty good – landing it in it in the 33rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Biogen's total ESG risk score against those of similar companies.

Biogen's environmental score

Environmental score: 1.02/100

Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Biogen's social score

Social score: 13.48/100

Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Biogen's governance score

Governance score: 8.43/100

Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Biogen's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Biogen Inc was last rated for ESG on: 2020-08-01.

Total ESG score 23.93
Total ESG percentile 33.4
Environmental score 1.02
Environmental score percentile 2
Social score 13.48
Social score percentile 2
Governance score 8.43
Governance score percentile 2
Level of controversy 2

Biogen share dividends

We're not expecting Biogen to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

You may also wish to consider:

Have Biogen's shares ever split?

Biogen's shares were split on a 3:1 basis on 18 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.

Biogen share price volatility

Over the last 12 months, Biogen's shares have ranged in value from as little as $219.7 up to $374.99. A popular way to gauge a stock's volatility is its "beta".

BIIB.US volatility(beta: 0.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.5234. This would suggest that Biogen's shares are less volatile than average (for this exchange).

To put Biogen's beta into context you can compare it against those of similar companies.

Biogen overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site